biotech

biotech Articles

Merrimack Pharmaceuticals shares saw a handy gain early Tuesday after the company announced positive results for its late stage metastatic pancreatic cancer study.
When Illumina issued an update on its sales for the third quarter, the numbers came in below what analysts were looking for, and as a result investors sent the stock lower.
IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) is watching its shares jump on Monday after the company announced that it received a tentative approval from the U.S. Food and Drug...
Several analysts have weighed in with higher price targets on top of their ratings for Tesaro. Its shares hit a new 52-week high on Monday.
On Monday morning, Merck, Mylan and Bristol-Myers Squibb made substantial runs, either up or down.
Shares of Exelixis saw a handy gain early Monday morning after the company reported positive results from its mid-stage trial for the treatment of renal cell carcinoma.
CRISPR Therapeutics expects to price more than 4 million shares in the range of $15 to $17 apiece for an initial public offering valued up to nearly $92 million.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has been on a meteoric rise over the past month. In this time the stock has gained over 150%, on what has been relatively little news for such a massive...
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
Shares of Immunomedics dropped sharply on Wednesday after the company announced the pricing of its secondary offering.
Trinity Biotech PLC (NASDAQ: TRIB) is watching its shares get halved on Tuesday after the company announced that it would withdraw one of its submissions to the U.S. Food and Drug Administration....
Shares of Summit Therapeutics more than doubled on Tuesday after it was announced that it would be entering into a licensing deal with Sarepta Therapeutics.
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
Jaguar Animal Health Inc. (NASDAQ: JAGX) filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. The expected price of the 4.32 million shares is...